ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has cleared the Omnipod Go for use by adults ...

Insulet Corp. has taken the lead in the race to bring insulin delivery systems to individuals with type 2 diabetes with U.S. FDA clearance of its Omnipod Go device. The delivery system is adapted for ...

The FDA cleared Omnipod GO, a tubeless, basal-only insulin pump for adult patients with type 2 diabetes typically using daily injections of long-acting insulin, said maker Insulet. Missouri is slated ...

Diabetes is a chronic health condition affecting blood glucose levels. In some cases, it requires constant management in the form of monitoring blood glucose levels and administering insulin.

A year into the rollout of the Omnipod 5 pump, Insulet is still riding high on the automated insulin delivery system’s ever-increasing popularity. Not only did the increase top the highs set in the ...

Insulet generated stellar third-quarter results that slightly exceeded our full-year expectations on the top and bottom lines. However, our fair value estimate is unchanged because our modest ...

“Omnipod GO was designed to serve the more than three million people using basal insulin or transitioning to insulin therapy to treat their type 2 diabetes,” said Jim Hollingshead, President and Chief ...